Abstract

Type 2 diabetes mellitus is a common metabolic disorder with immense social impact. Millions of patients are being treated with insulin either after primary failure or secondary failure with sulphonylurea therapy. Sulphonylureas have the potential to reduce the glucose levels by increasing the insulin secretion and insulin sensitivity. This study intends to know the effect on fasting and postprandial glucose levels on adding glibenclamide to daily insulin regimens and reduction of the dose of insulin requirement. Methods: The study conducted at Department of General Medicine, Siddartha Medical College, Vijaywada, Andhra Pradesh, India from July 2021 to June 2022. In 50 patients who met the inclusion criteria the fasting and postprandial glucose levels were recorded prior to the addition of glibenclamide and after addition of glibenclamide FBG and PPBG were recorded again and following statistical tests i.e., Fisher’s F test and Student’s ‘t’ test and Gaussian tests were used to find significance. Results: At the end of study FBG decreased by 32.5%which was statistically significant (p<0.01) and the mean PPBG value decreased by 27.7% which was also statistically significant (p<0.05). Conclusion: Combination therapy with insulin and glibenclamide results in a significant improvement in glycemic control compared to insulin therapy alone. Combination therapy has no significant effect on insulin dosage. Risk of hypoglycemia can be lowered if the dose of glibenclamide is tailored to each patient’s requirement. Compared to other insulin sensitizers’ traditional drug like glibenclamide is the cheapest and most economical option available currently in the Indian market.

Description